A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Lunesta drug warnings





FDA warns of next-day impairment with sleep aid Lunesta

11/15/2014
03:22 | Author: Caitlin White

Lunesta drug warnings
FDA warns of next-day impairment with sleep aid Lunesta

[ ] The U.S. Food and Drug Administration (FDA) is warning that the insomnia drug Lunesta (eszopiclone) can cause next-day.

Measures included tests of psychomotor coordination that are correlated with the ability to maintain a motor vehicle in the driving lane, tests of working memory, and subjective perception of sedation and coordination. In a double-blind study of 91 healthy adults between 25 and 40 years old, the effects of Lunesta 3 mg on psychomotor function were assessed the following morning, between 7.5 and 11.5 hours after dosing.

Comments (1)Read more



Lunesta Warnings and Precautions - Insomnia

11/14/2014
01:16 | Author: Evan Martin

Lunesta drug warnings
Lunesta Warnings and Precautions - Insomnia

This eMedTV page lists more Lunesta warnings and precautions, including Lunesta can interact with certain medications (see Lunesta Drug Interactions).

Marlborough, MA: Sepracor, Inc.;2004 December. Lunesta.

Comments (0)

F.D.A. Warns of Sleeping Pills39 Strange Effects - New York Times

9/13/2014
01:26 | Author: Devin Garcia

Lunesta drug screen
F.D.A. Warns of Sleeping Pills39 Strange Effects - New York Times

The F.D.A. ordered makers to print label warnings about risks and side of the well-known drugs Ambien and Lunesta and the producers of 11.

Comments (0)

FDA issues drug warning on Lunesta MetroWest495 Biz

7/12/2014
03:52 | Author: Evan Martin

Lunesta drug warnings
FDA issues drug warning on Lunesta MetroWest495 Biz

The U.S. Food and Drug Administration (FDA) is warning users of Lunesta, made by Marlborough's Sunovion Pharmaceuticals, that the.

The U.S. Food and Drug Administration (FDA) is warning users of Lunesta, made by Marlborough's Sunovion Pharmaceuticals, that the insomnia drug can cause next-day impairment of driving and other activities requiring alertness.

"We caution patients taking a 3-milligram dose against driving or engaging in other activities that require complete mental alertness the day after use," the FDA said.

Type your comment here:

Officials at Sunovion could not be reached for comment by deadline Wednesday morning.

The FDA said it's evaluating the risk of impaired mental alertness in all sleep aid drugs on the market, including over-the-counter drugs, and will issue updates as needed.

According to the FDA, a study found that the previously recommended starting dosage of 3 milligrams can "cause impairment of driving skills, memory and coordination that can last more than 11 hours after receiving an evening dose." The new recommended dose will result in less drug in the blood the next day.

The FDA said in a statement that it has decreased the recommended starting dosage of the drug to 1 milligram at bedtime, and that health care professionals should follow those recommendations when starting patients on Lunesta. The FDA said patients already taking the drug should continue their prescribed dose and contact their doctors to ask about the most appropriate dose for them.

Comments (0)

FDA orders lower doses for sleep drug Ambien, rival Lunesta

5/11/2014
05:50 | Author: Caitlin White

Lunesta drug warnings
FDA orders lower doses for sleep drug Ambien, rival Lunesta

The order does not affect the sleep drug Lunesta, made by a common side effect in the drug labels of all insomnia drugs, along with warnings.

Our daily opt-in push, TechFlash, delivers the day’s tech business headlines to the desktops of executives and entrepreneurs working throughout New England’s innovation economy.

An essential reference guide to New England Life Sciences companies, organizations and academic instructions.

The U.S. The new FDA guidelines are designed to protect patients from impairment by the drug the next day, and follows scores of reports of driving accidents related to sleep drug use. Food and Drug Administration will require the makers of sleep drug Ambien, and other insomnia medications containing the active ingredient zolpidem, to cut the recommended dosage in half, especially for women.

Sanjing Pharma Says Chairman Jumps to Death During Probe http://t.co/yjmlMm1iog via @ BloombergNews 20 May.

Puget Sound Business Journal Buffalo Business First.

But the agency said it would continue to evaluate the risk of impairment from other sleep aids, both prescription and over-the-counter.

Comments (5)Read more